–Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity–
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
“The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays. The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects. We look forward to our next data readout for SPU-21 by the end of the year or early 2024.”
-Eric Weisblum, Chief Executive Officer of Silo Pharma
The University of Maryland, Baltimore (UMB) is Silo Pharma’s collaboration partner for SPU-21 development. In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated.
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit www.silopharma.com